{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:19:59Z","timestamp":1790785199463,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T00:00:00Z","timestamp":1701648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T00:00:00Z","timestamp":1701648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Dexamethasone (DEX) induces CYP3A activity in a concentration-dependent manner. However, no study has examined changes in the blood concentration of CYP3A substrate drugs when DEX is administered at high doses. Herein, we present a case in which tacrolimus (TAC), a typical CYP3A substrate drug, was co-administered with a chemotherapy regimen that included high-dose DEX.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 71-year-old woman underwent liver transplantation for hepatocellular carcinoma 18\u00a0years prior to her inclusion in this case study. She was receiving TAC orally at 2\u00a0mg\/day and had a stable trough blood concentration of approximately 4\u00a0ng\/mL and a trough blood concentration\/dose (C\/D) ratio of approximately 2. The patient was diagnosed with post-transplant lymphoproliferative disease (histological type: Burkitt's lymphoma) after admission. Thereafter, the patient received cyclophosphamide-prednisolone (CP), followed by two courses of R-HyperCVAD (rituximab, cyclophosphamide, doxorubicin, vincristine, and DEX) and R-MA (rituximab, methotrexate, and cytarabine) replacement therapy. DEX (33\u00a0mg\/day) was administered intravenously on days 1\u20134 and days 11\u201314 of R-HyperCVAD treatment, and aprepitant (APR) was administered on days 1\u20135 in both courses. The TAC C\/D ratio decreased to approximately 1 on day 11 during both courses, and then increased. Furthermore, a decreasing trend in the TAC C\/D ratio was observed after R-MA therapy. The decrease in the TAC C\/D ratio was attributed to APR administration rather than to DEX.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The induction of CYP3A activity by a high dose of DEX may not be strong. The pharmacokinetic information on DEX and in vitro enzyme activity induction studies also suggested that CYP3A activity induction is not prominent under high-dose DEX treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40780-023-00310-0","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T00:02:02Z","timestamp":1701648122000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Induction of CYP3A activity by dexamethasone may not be strong, even at high doses: insights from a case of tacrolimus co-administration"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4727-8792","authenticated-orcid":false,"given":"Yoshiyuki","family":"Ohno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyohito","family":"Oriyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mineo","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tappei","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,4]]},"reference":[{"key":"310_CR1","unstructured":"Dexamethasone. Available from: https:\/\/www.uptodate.com\/contents\/dexamethasone-systemic-drug-information. Accessed 1 Jul 2023."},{"issue":"4","key":"310_CR2","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1067\/mcp.2000.110215","volume":"68","author":"JS McCune","year":"2000","unstructured":"McCune JS, Hawke RL, LeCluyse EL, Gillenwater HH, Hamilton G, Ritchie J, et al. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther. 2000;68(4):356\u201366. https:\/\/doi.org\/10.1067\/mcp.2000.110215.","journal-title":"Clin Pharmacol Ther"},{"key":"310_CR3","unstructured":"Dexametasone(HEMADY), Labeling-Package Insert, Revised: 6\/2021. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/211379s003lbl.pdf. Accessed 1 Jul 2023."},{"key":"310_CR4","unstructured":"Dexamethasone sodium phosphate(DECADRON), Labeling-Package Insert, Revised: 5\/2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/211379s003lbl.pdf. Accessed 1 Jul 2023."},{"issue":"9","key":"310_CR5","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/s0002-9343(02)01363-3","volume":"113","author":"JF Rogers","year":"2002","unstructured":"Rogers JF, Nafziger AN, Bertino JS Jr. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med. 2002;113(9):746\u201350. https:\/\/doi.org\/10.1016\/s0002-9343(02)01363-3.","journal-title":"Am J Med"},{"key":"310_CR6","doi-asserted-by":"publisher","first-page":"100414","DOI":"10.1016\/j.dmpk.2021.100414","volume":"41","author":"K Maeda","year":"2021","unstructured":"Maeda K, Hisaka A, Ito K, Ohno Y, Ishiguro A, Sato R, et al. Classification of drugs for evaluating drug interaction in drug development and clinical management. Drug Metab Pharmacokinet. 2021;41:100414. https:\/\/doi.org\/10.1016\/j.dmpk.2021.100414.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"3","key":"310_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/j.1600-0773.1998.tb01457.x","volume":"83","author":"K Villikka","year":"1998","unstructured":"Villikka K, Kivisto KT, Neuvonen PJ. The effect of dexamethasone on the pharmacokinetics of triazolam. Pharmacol Toxicol. 1998;83(3):135\u20138. https:\/\/doi.org\/10.1111\/j.1600-0773.1998.tb01457.x.","journal-title":"Pharmacol Toxicol"},{"issue":"2","key":"310_CR8","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1172\/JCI113933","volume":"83","author":"PB Watkins","year":"1989","unstructured":"Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. J Clin Invest. 1989;83(2):688\u201397. https:\/\/doi.org\/10.1172\/JCI113933.","journal-title":"J Clin Invest"},{"issue":"6","key":"310_CR9","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2165\/00003088-199529060-00003","volume":"29","author":"R Venkataramanan","year":"1995","unstructured":"Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995;29(6):404\u201330. https:\/\/doi.org\/10.2165\/00003088-199529060-00003.","journal-title":"Clin Pharmacokinet"},{"key":"310_CR10","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/00008571-200403000-00002","volume":"14","author":"V Haufroid","year":"2004","unstructured":"Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, Malaise J, Lison D, Squifflet JP, Wallemacq P. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics. 2004;14:147\u201354.","journal-title":"Pharmacogenetics"},{"issue":"3","key":"310_CR11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1177\/0091270003262950","volume":"44","author":"CR Shadle","year":"2004","unstructured":"Shadle CR, Lee Y, Majumdar AK, Petty KJ, Gargano C, Bradstreet TE, et al. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol. 2004;44(3):215\u201323. https:\/\/doi.org\/10.1177\/0091270003262950.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"310_CR12","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1007\/s11096-014-0022-y","volume":"36","author":"Y Ohno","year":"2014","unstructured":"Ohno Y, Yamada M, Yamaguchi R, Hisaka A, Suzuki H. Persistent drug interaction between aprepitant and warfarin in patients receiving anticancer chemotherapy. Int J Clin Pharm. 2014;36(6):1134\u20137. https:\/\/doi.org\/10.1007\/s11096-014-0022-y.","journal-title":"Int J Clin Pharm"},{"issue":"5","key":"310_CR13","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1248\/bpb.b16-00014","volume":"39","author":"J Takaki","year":"2016","unstructured":"Takaki J, Ohno Y, Yamada M, Yamaguchi R, Hisaka A, Suzuki H. Assessment of drug-drug Interaction between warfarin and aprepitant and its effects on PT-INR of patients receiving anticancer chemotherapy. Biol Pharm Bull. 2016;39(5):863\u20138. https:\/\/doi.org\/10.1248\/bpb.b16-00014.","journal-title":"Biol Pharm Bull"},{"issue":"10\u201311","key":"310_CR14","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1080\/00498250701534893","volume":"37","author":"NJ Hewitt","year":"2007","unstructured":"Hewitt NJ, Lecluyse EL, Ferguson SS. Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations. Xenobiotica. 2007;37(10\u201311):1196\u2013224. https:\/\/doi.org\/10.1080\/00498250701534893.","journal-title":"Xenobiotica"},{"issue":"5","key":"310_CR15","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1517\/17460441003762717","volume":"5","author":"M Honma","year":"2010","unstructured":"Honma M, Kozawa M, Suzuki H. Methods for the quantitative evaluation and prediction of CYP enzyme induction using human in vitro systems. Expert Opin Drug Discov. 2010;5(5):491\u2013511. https:\/\/doi.org\/10.1517\/17460441003762717.","journal-title":"Expert Opin Drug Discov"},{"issue":"4","key":"310_CR16","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1345\/aph.1H423","volume":"41","author":"JR Horn","year":"2007","unstructured":"Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007;41(4):674\u201380. https:\/\/doi.org\/10.1345\/aph.1H423.","journal-title":"Ann Pharmacother"},{"key":"310_CR17","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1093\/ndt\/gfy096","volume":"33","author":"F Stifft","year":"2018","unstructured":"Stifft F, van Kuijk SMJ, Bekers O, Christiaans MHL. Increase in tacrolimus exposure after steroid tapering is influenced by CYP3A5 and pregnane X receptor genetic polymorphisms in renal transplant recipients. Nephrol Dial Transplant. 2018;33:1668\u201375. https:\/\/doi.org\/10.1093\/ndt\/gfy096.","journal-title":"Nephrol Dial Transplant"},{"key":"310_CR18","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0009-9236(03)00168-1","volume":"74","author":"DA Hesselink","year":"2003","unstructured":"Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 2003;74:245\u201354. https:\/\/doi.org\/10.1016\/S0009-9236(03)00168-1.","journal-title":"Clin Pharmacol Ther"},{"key":"310_CR19","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1200\/JCO.1997.15.5.1906","volume":"15","author":"L Gianni","year":"1997","unstructured":"Gianni L, Vigano L, Locatelli A, Capri G, Giani A, Tarenzi E, et al. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol. 1997;15:1906\u201315. https:\/\/doi.org\/10.1200\/JCO.1997.15.5.1906.","journal-title":"J Clin Oncol"},{"key":"310_CR20","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrd1984","volume":"5","author":"G Szakacs","year":"2006","unstructured":"Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5:219\u201334. https:\/\/doi.org\/10.1038\/nrd1984.","journal-title":"Nat Rev Drug Discov"},{"key":"310_CR21","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1124\/dmd.106.009902","volume":"34","author":"JB Dennison","year":"2006","unstructured":"Dennison JB, Kulanthaivel P, Barbuch RJ, Renbarger JL, Ehlhardt WJ, Hall SD. Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos. 2006;34:1317\u201327. https:\/\/doi.org\/10.1124\/dmd.106.009902.","journal-title":"Drug Metab Dispos"},{"key":"310_CR22","first-page":"16","volume":"25","author":"M D'Incalci","year":"1998","unstructured":"D\u2019Incalci M, Schuller J, Colombo T, Zucchetti M, Riva A. Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations. Semin Oncol. 1998;25:16\u201320.","journal-title":"Semin Oncol"},{"key":"310_CR23","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1097\/00005344-198509000-00030","volume":"7","author":"J Kuhlmann","year":"1985","unstructured":"Kuhlmann J, Woodcock B, Wilke J, Welling H, Rietbrock N. Verapamil plasma concentrations during treatment with cytostatic drugs. J Cardiovasc Pharmacol. 1985;7:1003\u20136. https:\/\/doi.org\/10.1097\/00005344-198509000-00030.","journal-title":"J Cardiovasc Pharmacol"},{"key":"310_CR24","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s40262-020-00922-x","volume":"59","author":"R Kirubakaran","year":"2020","unstructured":"Kirubakaran R, Stocker SL, Hennig S, Day RO, Carland JE. Population pharmacokinetic models of tacrolimus in adult transplant recipients: A systematic review. Clin Pharmacokinet. 2020;59:1357\u201392. https:\/\/doi.org\/10.1007\/s40262-020-00922-x.","journal-title":"Clin Pharmacokinet"},{"key":"310_CR25","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/bcpt.13539","volume":"128","author":"T Enokiya","year":"2021","unstructured":"Enokiya T, Nishikawa K, Hamada Y, Ikemura K, Sugimura Y, Okuda M. Temporary decrease in tacrolimus clearance in cytochrome P450 3A5 non-expressors early after living donor kidney transplantation: Effect of interleukin 6-induced suppression of the cytochrome P450 3A gene. Basic Clin Pharmacol Toxicol. 2021;128:525\u201333. https:\/\/doi.org\/10.1111\/bcpt.13539.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"310_CR26","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.3390\/pharmaceutics13111960","volume":"13","author":"A Chavant","year":"2021","unstructured":"Chavant A, Fonrose X, Gautier-Veyret E, Hilleret MN, Roustit M, Stanke-Labesque F. Variability of tacrolimus trough concentration in liver transplant patients: Which role of inflammation? Pharmaceutics. 2021;13:1960. https:\/\/doi.org\/10.3390\/pharmaceutics13111960.","journal-title":"Pharmaceutics"},{"key":"310_CR27","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00228-022-03275-5","volume":"78","author":"H Hibino","year":"2022","unstructured":"Hibino H, Sakiyama N, Makino Y, Makihara-Ando R, Horinouchi H, Fujiwara Y, et al. Evaluation of hepatic CYP3A enzyme activity using endogenous markers in lung cancer patients treated with cisplatin, dexamethasone, and aprepitant. Eur J Clin Pharmacol. 2022;78:613\u201321. https:\/\/doi.org\/10.1007\/s00228-022-03275-5.","journal-title":"Eur J Clin Pharmacol"},{"key":"310_CR28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/cpt1975182205","volume":"18","author":"DE Duggan","year":"1975","unstructured":"Duggan DE, Yeh KC, Matalia N, Ditzler CA, McMahon FG. Bioavailability of oral dexamethasone. Clin Pharmacol Ther. 1975;18:205\u20139. https:\/\/doi.org\/10.1002\/cpt1975182205.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-023-00310-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-023-00310-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-023-00310-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T00:03:08Z","timestamp":1701648188000},"score":1,"resource":{"primary":{"URL":"https:\/\/jphcs.biomedcentral.com\/articles\/10.1186\/s40780-023-00310-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,4]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["310"],"URL":"https:\/\/doi.org\/10.1186\/s40780-023-00310-0","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,4]]},"assertion":[{"value":"3 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional review board of the Graduate School of Medicine and Faculty of Medicine, The University of Tokyo (Approval numbers: 2654-11. This study received general consent. Nevertheless, as this was a case study performed using data obtained from routine medical care, the study was conducted with full consideration of protecting patient\u2019s personal information according to the guidelines on privacy policy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}